Literature DB >> 7690926

Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.

F Loganzo1, J S Dosik, Y Zhao, M J Vidal, D M Nanus, M Sudol, A P Albino.   

Abstract

The c-yes proto-oncogene encodes a protein tyrosine kinase, p62c-yes (c-Yes) that belongs to the Src family of non-receptor type protein tyrosine kinases. We compared the levels of c-Yes kinase activity and protein by immune complex kinase assays and immune blot analysis in 20 human melanoma and 10 human melanocyte cell lines. Results show that the average kinase activity of c-Yes in most melanoma cell lines is 5-10-fold higher than that in melanocyte cell lines. The protein level of c-Yes in these melanoma cell lines is correspondingly higher than that in melanocytes. The increase in c-Yes kinase activity is most likely attributable to the elevated protein level because single-strand conformational polymorphism of all structural and functional domains detected no mutations in any of the c-yes coding regions. Subcellular fractionation analysis indicated that c-Yes localizes to the plasma membrane, perinuclear and cytosolic compartments while c-Src predominantly associates with plasma membranes. In melanoma cells in which an elevated level of c-Yes is observed, a protein of 39 kD is heavily phosphorylated on tyrosine. This protein is only observed in melanoma cells and not in melanocytes, suggesting a perturbed signaling pathway in melanoma cells that results in abnormal tyrosine phosphorylation of cellular proteins. These data suggest that derangement of expression of the c-Yes tyrosine kinase may have a role in the malignant progression of the human melanocyte.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690926

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

2.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

3.  Activation of c-Yes in hepatocellular carcinoma: a preliminary study.

Authors:  Han Feng; Tsutomu Masaki; Takako Nonomura; Asahiro Morishita; Gong Jian; Seiji Nakai; Akihiro Deguchi; Naohito Uchida; Takashi Himoto; Hisakazu Iwama; Hisashi Usuki; Hisao Wakabayashi; Kunihiko Izuishi; Hitoshi Yoshiji; Kazutaka Kurokohchi; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

4.  Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3.

Authors:  Kazunori Hamamura; Momoko Tsuji; Hiroshi Hotta; Yuki Ohkawa; Masataka Takahashi; Hidenobu Shibuya; Hideyuki Nakashima; Yoshio Yamauchi; Noboru Hashimoto; Hisashi Hattori; Minoru Ueda; Keiko Furukawa; Koichi Furukawa
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

5.  In vitro studies of dasatinib, its targets and predictors of sensitivity.

Authors:  Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Ashok Chakraborty; Michael A Davies; Robert L Camp; David L Rimm; Arkadiusz Dudek; Mario Sznol; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2011-04       Impact factor: 4.693

6.  Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells.

Authors:  J Park; C A Cartwright
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

7.  Elevated c-Src and c-Yes expression in malignant skin cancers.

Authors:  Jang Hyun Lee; Jae-Kyung Pyon; Dong Wook Kim; Sang Han Lee; Hae Seon Nam; Chul Han Kim; Sang Gue Kang; Yoon Jin Lee; Mi Youn Park; Dong Jun Jeong; Moon Kyun Cho
Journal:  J Exp Clin Cancer Res       Date:  2010-08-27

8.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

9.  Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Authors:  Alex J Eustace; John Crown; Martin Clynes; Norma O'Donovan
Journal:  J Transl Med       Date:  2008-09-29       Impact factor: 5.531

10.  Src, PKCalpha, and PKCdelta are required for alphavbeta3 integrin-mediated metastatic melanoma invasion.

Authors:  Andrew J Putnam; Veronique V Schulz; Eric M Freiter; Heather M Bill; Cindy K Miranti
Journal:  Cell Commun Signal       Date:  2009-04-28       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.